# A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients

> **NCT06703268** · PHASE2 · COMPLETED · sponsor: **Haisco Pharmaceutical Group Co., Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** HSK7653 10 mg
- **DRUG:** Daily DPP-4 inhibitor

## Key facts

- **NCT ID:** NCT06703268
- **Lead sponsor:** Haisco Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-15
- **Primary completion:** 2024-10-05
- **Final completion:** 2024-11-20
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2024-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703268, "A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06703268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*